Study Reveals Neural Basis of Apathy in Schizophrenia
Recent research from the University of Geneva reveals the neural mechanisms connecting schizophrenia and apathy, shedding light on the debilitating impact of this condition. The study uncovers how individuals with schizophrenia struggle to differentiate between rewards, leading to reduced motivation and hindered task performance. The findings offer new insights into potential treatments, such as targeted brain stimulation and specialized psychotherapy interventions, to support individuals with schizophrenia.
Groundbreaking Studies Shed Light on Mental Health Disorders
Two groundbreaking studies conducted by scientists from The Mount Sinai Hospital as part of the PsychENCODE Consortium offer valuable insights into the molecular biology of neuropsychiatric diseases. Published in a special issue of Science, these studies provide detailed understanding of the molecular alterations associated with schizophrenia and present a population-scale map of the brain’s regulatory components. Dr. Panos Roussos, the senior author, emphasizes the importance of these findings in advancing innovative treatments for mental health disorders.
Link Between Schizophrenia and Aging Uncovered in New Study
Recent research published in Nature suggests a potential link between schizophrenia and aging, revealing coordinated changes in gene expression activity in neurons and astrocytes as a key factor. The study’s findings offer valuable insights into the potential biological underpinnings of cognitive decline in schizophrenia and aging, providing hope for future targeted interventions and therapies.
Schizophrenia linked to increased risk for subsequent CVD events
A study published in the Journal of the American Heart Association found that schizophrenia is associated with an increased risk of subsequent cardiovascular disease (CVD) events, with the association stronger in women. The researchers observed a significant relationship of schizophrenia with an increased risk for developing composite CVD events in both men and women, with a stronger association seen in women. The study suggests a need for greater support for individuals, particularly women, with schizophrenia, and for psychiatrists, cardiologists, and general physicians to apply these findings to CVD prevention.
FDA Grants Breakthrough Device Designation to Click Therapeutics’ CT-155 for Schizophrenia Treatment
Click Therapeutics’ prescription digital therapeutic (PDT) CT-155 has been granted Breakthrough Device designation by the FDA for the treatment of negative symptoms of schizophrenia in adults. The smartphone app, developed in collaboration with Boehringer Ingelheim, is currently being investigated in…
Study Raises Concerns About Generalizability of Clinical Prediction Models in AI Healthcare
A recent study published in the journal Science has raised concerns about the generalizability of clinical prediction models, particularly in the context of artificial intelligence (AI) in healthcare. The study, conducted by Adam M. Chekroud, Matt Hawrilenko, Hieronimus Loho, Julia…